82 related articles for article (PubMed ID: 1999848)
1. Endometrial cancer: biochemical and clinical correlates.
Gurpide E
J Natl Cancer Inst; 1991 Mar; 83(6):405-16. PubMed ID: 1999848
[TBL] [Abstract][Full Text] [Related]
2. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.
Smith HO; Anderson PS; Kuo DY; Goldberg GL; DeVictoria CL; Boocock CA; Jones JG; Runowicz CD; Stanley ER; Pollard JW
Clin Cancer Res; 1995 Mar; 1(3):313-25. PubMed ID: 9815987
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells.
Gong Y; Ballejo G; Murphy LC; Murphy LJ
Cancer Res; 1992 Apr; 52(7):1704-9. PubMed ID: 1551100
[TBL] [Abstract][Full Text] [Related]
4. Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract.
Zhang X; Silva E; Gershenson D; Hung MC
Oncogene; 1989 Aug; 4(8):985-9. PubMed ID: 2569708
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma.
Bonte J; Ide P; Billiet G; Wynants P
Gynecol Oncol; 1981 Apr; 11(2):140-61. PubMed ID: 6783481
[No Abstract] [Full Text] [Related]
6. Transforming growth factor gene expression in human endometrial adenocarcinoma cells: regulation by progestins.
Gong Y; Anzai Y; Murphy LC; Ballejo G; Holinka CF; Gurpide E; Murphy LJ
Cancer Res; 1991 Oct; 51(20):5476-81. PubMed ID: 1833051
[TBL] [Abstract][Full Text] [Related]
7. Morphology of human uterine cancer in nude mice. Effects of hormone and antihormone treatment.
Zaino RJ; Satyaswaroop PG; Mortel R
Arch Pathol Lab Med; 1984 Jul; 108(7):571-8. PubMed ID: 6547322
[TBL] [Abstract][Full Text] [Related]
8. Oncogenes and growth factors in thyroid carcinogenesis.
Frauman AG; Moses AC
Endocrinol Metab Clin North Am; 1990 Sep; 19(3):479-93. PubMed ID: 2175702
[TBL] [Abstract][Full Text] [Related]
9. [Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors].
Nishida M; Kasahara K; Kaneko M; Iwasaki H; Hayashi K
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jul; 37(7):1103-11. PubMed ID: 4031568
[TBL] [Abstract][Full Text] [Related]
10. Endometrial cancer: histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor.
Segreti EM; Novotny DB; Soper JT; Mutch DG; Creasman WT; McCarty KS
Obstet Gynecol; 1989 May; 73(5 Pt 1):780-5. PubMed ID: 2704506
[TBL] [Abstract][Full Text] [Related]
11. High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas.
Kacinski BM; Carter D; Mittal K; Kohorn EI; Bloodgood RS; Donahue J; Donofrio L; Edwards R; Schwartz PE; Chambers JT
Int J Radiat Oncol Biol Phys; 1988 Oct; 15(4):823-9. PubMed ID: 3182322
[TBL] [Abstract][Full Text] [Related]
12. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
[TBL] [Abstract][Full Text] [Related]
13. [Histopathological changes in endometrial cancer treated with tamoxifen].
Lin HH; Ueda K; Kato J
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1038-43. PubMed ID: 3963849
[TBL] [Abstract][Full Text] [Related]
14. [In vitro study for hormones and growth factors dependent cell proliferation of endometrial adenocarcinoma cells].
Hata H; Hamano M; Tsujii A; Togasaki Y; Kuramoto H; Nishida M; Anzai Y; Gurpide E
Hum Cell; 1993 Sep; 6(3):182-7. PubMed ID: 8297814
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-beta negatively modulates proliferation and c-fos expression of the human endometrial adenocarcinoma cell line HEC-1-A.
Bergman CA; Talavera F; Christman GM; Baker VV; Roberts JA; Menon KM
Gynecol Oncol; 1997 Apr; 65(1):63-8. PubMed ID: 9103392
[TBL] [Abstract][Full Text] [Related]
16. [Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer].
Thurzó L
Zentralbl Gynakol; 1990; 112(17):1111-5. PubMed ID: 2148245
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Slavik M; Petty WM; Blessing JA; Creasman WT; Homesley HD
Cancer Treat Rep; 1984 May; 68(5):809-11. PubMed ID: 6722836
[No Abstract] [Full Text] [Related]
18. [Role of p185c-erbB2 in endometrial cancer growth in vitro].
Sakamoto H; Ohtani K; Ohta H; Takami M; Takami T; Satoh K
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jul; 44(7):800-4. PubMed ID: 1354238
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
